174 related articles for article (PubMed ID: 38712716)
1. Clinical trial evaluating apomorphine oromucosal solution in Parkinson's disease patients.
Thijssen E; Tuk B; Cakici M; van Velze V; Klaassen E; Merkus F; van Laar T; Kremer P; Groeneveld GJ
Clin Transl Sci; 2024 May; 17(5):e13796. PubMed ID: 38712716
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic analysis of apomorphine sublingual film or subcutaneous apomorphine in healthy subjects and patients with Parkinson's disease.
Agbo F; Crass RL; Chiu YY; Chapel S; Galluppi G; Blum D; Navia B
Clin Transl Sci; 2021 Jul; 14(4):1464-1475. PubMed ID: 33650272
[TBL] [Abstract][Full Text] [Related]
3. A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease.
van Laar T; Neef C; Danhof M; Roon KI; Roos RA
Mov Disord; 1996 Nov; 11(6):633-8. PubMed ID: 8914088
[TBL] [Abstract][Full Text] [Related]
4. Long-term safety, tolerability and efficacy of apomorphine sublingual film in patients with Parkinson's disease complicated by OFF episodes: a phase 3, open-label study.
Kassubek J; Factor SA; Balaguer E; Schwarz J; Chaudhuri KR; Isaacson SH; Wu S; Denecke Muhr C; Kulisevsky J
J Neurol; 2024 Jun; 271(6):3554-3570. PubMed ID: 38546829
[TBL] [Abstract][Full Text] [Related]
5. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study.
Olanow CW; Factor SA; Espay AJ; Hauser RA; Shill HA; Isaacson S; Pahwa R; Leinonen M; Bhargava P; Sciarappa K; Navia B; Blum D;
Lancet Neurol; 2020 Feb; 19(2):135-144. PubMed ID: 31818699
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories.
van Laar T; Jansen EN; Neef C; Danhof M; Roos RA
Mov Disord; 1995 Jul; 10(4):433-9. PubMed ID: 7565822
[TBL] [Abstract][Full Text] [Related]
7. Dose optimization of apomorphine sublingual film for treating "OFF" episodes in Parkinson's disease.
Olanow CW; Stocchi F; Peckham EL; De Pandis MF; Sciarappa K; Navia B
Parkinsonism Relat Disord; 2021 Dec; 93():27-30. PubMed ID: 34763305
[TBL] [Abstract][Full Text] [Related]
8. Sublingual apomorphine: a new pharmacological approach in Parkinson's disease?
Montastruc JL; Rascol O; Senard JM; Houin G; Rascol A
J Neural Transm Suppl; 1995; 45():157-61. PubMed ID: 8748621
[TBL] [Abstract][Full Text] [Related]
9. Subcutaneous apomorphine : an evidence-based review of its use in Parkinson's disease.
Deleu D; Hanssens Y; Northway MG
Drugs Aging; 2004; 21(11):687-709. PubMed ID: 15323576
[TBL] [Abstract][Full Text] [Related]
10. Sublingual apomorphine in treatment of Parkinson's disease: a review.
Hislop J; Margolesky J; Shpiner DS
Int J Neurosci; 2024 May; 134(5):474-480. PubMed ID: 35986574
[TBL] [Abstract][Full Text] [Related]
11. Apomorphine pharmacokinetics in parkinsonism after intranasal and subcutaneous application.
Sam E; Jeanjean AP; Maloteaux JM; Verbeke N
Eur J Drug Metab Pharmacokinet; 1995; 20(1):27-33. PubMed ID: 7588990
[TBL] [Abstract][Full Text] [Related]
12. Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and "OFF" episodes.
Hui JS; Fox SH; Neeson W; Bhargava P; Pappert E; Blum D; Navia B;
Parkinsonism Relat Disord; 2020 Oct; 79():110-116. PubMed ID: 32927285
[TBL] [Abstract][Full Text] [Related]
13. Subcutaneous apomorphine in patients with advanced Parkinson's disease: a dose-escalation study with randomized, double-blind, placebo-controlled crossover evaluation of a single dose.
Pahwa R; Koller WC; Trosch RM; Sherry JH;
J Neurol Sci; 2007 Jul; 258(1-2):137-43. PubMed ID: 17466338
[TBL] [Abstract][Full Text] [Related]
14. Role of apomorphine in the treatment of Parkinson's disease.
Boyle A; Ondo W
CNS Drugs; 2015 Feb; 29(2):83-9. PubMed ID: 25676564
[TBL] [Abstract][Full Text] [Related]
15. A review of intermittent subcutaneous apomorphine injections for the rescue management of motor fluctuations associated with advanced Parkinson's disease.
Chen JJ; Obering C
Clin Ther; 2005 Nov; 27(11):1710-24. PubMed ID: 16368444
[TBL] [Abstract][Full Text] [Related]
16. Sublingual apomorphine (APL-130277) for the acute conversion of OFF to ON in Parkinson's disease.
Hauser RA; Olanow CW; Dzyngel B; Bilbault T; Shill H; Isaacson S; Dubow J; Agro A
Mov Disord; 2016 Sep; 31(9):1366-72. PubMed ID: 27430123
[TBL] [Abstract][Full Text] [Related]
17. Open-label study assessment of safety and adverse effects of subcutaneous apomorphine injections in treating "off" episodes in advanced Parkinson disease.
LeWitt PA; Ondo WG; Van Lunen B; Bottini PB
Clin Neuropharmacol; 2009; 32(2):89-93. PubMed ID: 18978491
[TBL] [Abstract][Full Text] [Related]
18. A Randomized Controlled Trial of Subcutaneous Apomorphine for Parkinson Disease: A Repeat Dose and Pharmacokinetic Study.
Nomoto M; Kubo S; Nagai M; Yamada T; Tamaoka A; Tsuboi Y; Hattori N;
Clin Neuropharmacol; 2015; 38(6):241-7. PubMed ID: 26536022
[TBL] [Abstract][Full Text] [Related]
19. Subcutaneously administered apomorphine: pharmacokinetics and metabolism.
LeWitt PA
Neurology; 2004 Mar; 62(6 Suppl 4):S8-11. PubMed ID: 15037665
[TBL] [Abstract][Full Text] [Related]
20. Inhaled apomorphine in patients with 'on-off' fluctuations: a randomized, double-blind, placebo-controlled, clinic and home based, parallel-group study.
Grosset KA; Malek N; Morgan F; Grosset DG
J Parkinsons Dis; 2013; 3(1):31-7. PubMed ID: 23938309
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]